Erectile dysfunction and the "window of curability": A harbinger of cardiovascular events

Mayo Clinic Proceedings

Volumn 84, Issue 2, 2009, Pages 102-104

  Miner, Martin M ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ROSUVASTATIN; PHOSPHODIESTERASE INHIBITOR;

ATHEROSCLEROSIS; CLINICAL TRIAL; EDITORIAL; ERECTILE DYSFUNCTION; HEART DISEASE; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIFESTYLE; RISK FACTOR; STROKE; UNSTABLE ANGINA PECTORIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; MALE; MIDDLE AGED; NOTE; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHODIESTERASE INHIBITORS; STROKE;

EID: 61449094753     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/84.2.102     Document Type: Editorial

References (12)

1. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996-3002.
2. Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008;51(21):2040-2044.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
4. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov;359(21):2195-2207. Epub 2007 Nov 9.
5. Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary artery disease in type 2 diabetes. J Am Coll Cardiol. 2008;51(21):2045-2050.
6. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med. 2006;3(1):28-36.
7. Nehra A. Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. Mayo Clin Proc. 2009;84(2):139-148.
8. Inman BA, St. Sauver JL, Jacobson DJ, et al. A population-based longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009;84(2):108-113.
9. Mykletun A, Dahl AA, O'Leary MP, Fosså SD. Assessment of male sexual function by the Brief Sexual Function Inventory. BJU Int. 2006;97(2):316-323.
10. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer-Verlag; 2000.
11. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder [editorial]? Eur Urol. 2003;44(3):352-354.
12. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007 Jul;50(1):1-13. Epub 2007 Jun 18.